AOP Orphan Pharmaceuticals

Company snapshot

AOP Orphan Pharmaceuticals is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Pulmonary Arterial Hypertension (PAH). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1), phase 3 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for AOP Orphan Pharmaceuticals. Not investment advice.

• What is AOP Orphan Pharmaceuticals?

  AOP Orphan Pharmaceuticals is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Pulmonary Arterial Hypertension (PAH). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA,

• Is AOP Orphan Pharmaceuticals publicly traded?

  AOP Orphan Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does AOP Orphan Pharmaceuticals develop or market?

  We link 1 drug profile(s) where AOP Orphan Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aop-orphan-pharmaceuticals-gmbh#company-drugs.

• What are the latest developments for AOP Orphan Pharmaceuticals?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does AOP Orphan Pharmaceuticals focus on?

  AOP Orphan Pharmaceuticals focuses on Pulmonary Arterial Hypertension (PAH) based on our analysis of their pipeline programs and drug development activities.